Genentech, Inc.

This early-stage trial is testing a drug called vixarelimab in 24 people with moderate to severe ulcerative colitis who have not improved with standard treatments. The study looks at how the drug affects the gut, how it moves through the body, and whether it is safe. It is too ea…

This early-stage study tests a new drug called belvarafenib, alone or with other drugs (cobimetinib and nivolumab), in people with advanced melanoma that has a specific NRAS gene change and has stopped responding to standard immunotherapy. The main goals are to check safety and f…

This study tests a new drug, giredestrant, combined with everolimus against standard hormone therapy plus everolimus in people with a common type of advanced breast cancer (ER+/HER2-). About 373 participants who have already tried other treatments will be enrolled. The goal is to…

This early-phase study tests a new drug called inavolisib in people with advanced solid tumors or breast cancer that have a specific PIK3CA gene mutation. The study aims to find a safe dose and see how well the drug works alone or with other cancer treatments. About 200 participa…

This early-stage study tests a new drug, RO7497372, given as an eye injection for people with diabetic macular edema (DME), a condition that causes vision loss. The trial involves 151 participants and aims to check the drug's safety, how long it stays in the eye and blood, and it…

This phase 2 trial tests a drug called mosunetuzumab, given as a shot under the skin, for people with certain types of non-Hodgkin lymphoma. The study includes 320 participants and aims to see if the drug can shrink tumors or delay cancer growth. Researchers are also checking for…

This early-phase study tests a new drug, GDC-6036, in people with advanced cancers (like lung or colorectal) that have a specific KRAS G12C mutation. The goal is to check safety and find the right dose, both when used alone and with other cancer drugs. About 498 participants will…

This early-stage trial tests a new drug called runimotamab, alone or with trastuzumab, in 123 people with advanced HER2-positive cancers. The main goal is to check safety and how the drug moves through the body. It is for patients whose cancer has spread or cannot be removed by s…

This study tests a drug called faricimab (VABYSMO) in 218 people with diabetic macular edema who have not been treated before. The participants are Black/African American, Hispanic/Latino American, Native American/Alaska Native/Native Hawaiian/Pacific Islander, or Asian Indian. T…

This study tests an experimental drug called XmAb24306, given alone or with another cancer drug (atezolizumab), in people with advanced solid tumors that cannot be cured. The main goal is to check the drug's safety and how the body processes it. About 195 participants will take p…

This early-phase study tests a new drug (XmAb24306) combined with another drug (cevostamab) in people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The main goal is to check safety and find the right dose. About 90 participants…

This early-stage trial is testing a new drug called GDC-9545 (giredestrant), alone or combined with other medications, in people with advanced ER-positive breast cancer that has spread. The main goals are to check safety, find the best dose, and see if it shrinks tumors. About 18…

This early-stage study tests an experimental cell therapy called P-CD19CD20-ALLO1 in 60 adults with multiple sclerosis. The main goal is to see if it is safe and how the body handles it. Researchers will also measure how long the cells last and how they affect the immune system.

This study follows 403 adults and children with spinal muscular atrophy who are already taking risdiplam (Evrysdi) as prescribed by their doctor. Researchers will track side effects and how well the drug works over about two years. The goal is to see if risdiplam remains safe and…

This early-phase trial is testing an experimental antibody called cevostamab, either alone or combined with other drugs (pomalidomide, daratumumab, and dexamethasone), in 126 people with multiple myeloma that has returned or stopped responding to treatment. The main goals are to …

This phase 2 trial is testing whether adding venetoclax to standard BTK inhibitor therapy can help people with chronic lymphocytic leukemia (CLL) achieve very deep remission. The goal is to see if patients can then safely stop all treatment for a period. The study involves 118 ad…

This study offers continued treatment with trastuzumab emtansine (Kadcyla), alone or with other drugs, to 720 patients with metastatic cancer who were already benefiting from it in a previous trial. The main goal is to monitor long-term safety and side effects. It is an open-labe…

This study follows 400 people with intermediate age-related macular degeneration (AMD) for about 3 years. Researchers watch how the disease advances to more severe stages and test if measuring the loss of light-sensing cells in the eye can be a useful way to track the disease. No…

This study checks if two different devices for injecting trastuzumab under the skin work the same way in the body. It involves 312 healthy men who will get a single dose. The goal is to see if the drug levels are similar, not to treat any disease.